Frank J. Gonzalez
Senior Investigator
Laboratory of Metabolism, Nucleic Acids Section, CCR
National Cancer Institute
United States of America
Biography
Dr. Gonzalez received his Ph.D. from the University of Wisconsin in Madison and was a staff fellow at the National Institute of Child Health and Human Development prior to joining the NCI. He received the Rawls Palmer Progress in Medicine Award from the American Society for Clinical Pharmacology, the John J. Abel Award and the Bernard B. Brodie Award in Drug Metabolism from the American Society of Pharmacology and Experimental Therapeutics, the George Scott Award from the Toxicology Forum, the North American Achievement Award from the International Society for the Study of Xenobiotics, the Elizabeth and James Miller Award in Experimental Oncology and an honorary D.Sc. from Mahidol University, Thailand. Dr. Gonzalez is an honorary member of the Society of Toxicology and an honorary fellow of the Royal College of Physicians of Thailand. He is a 14-time recipient of the Federal Technology Transfer Award and has three NIH Merit Awards. He is the co-inventor of 18 patents. His studies are largely focused on the role of cytochromes P450 and xenobiotic receptors in drug metabolism and chemical carcinogenesis.
Research Interest
1) Nuclear receptor signaling, 2) Metabolomics, 3) Metagenomics, 4) Metabolic diseases, 5) Genetically engineered mice, 6) Cancer Biology, 7) Chemical Biology, 8) Molecular 9) Biology and Biochemistry, 10) Molecular Pharmacology, 11) Systems Biology.
Publications
-
Intestine-selective farnesoid X receptor inhibition improves obesity-related metabolic dysfunction.
-
Microbiome remodeling leads to inhibition of intestinal farnesoid X receptor signaling and decreased obesity.
-
St. John's Wort Attenuates Colorectal Carcinogenesis in Mice through Suppression of Inflammatory Signaling.
